ANIP - ANI Pharmaceuticals reports Q3 earnings miss; reaffirms FY22 guidance
- ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q3 Non-GAAP EPS of $0.64 beats by $0.09 .
- Revenue of $83.8M (+61.0% Y/Y) beats by $5.44M .
- Adjusted non-GAAP EBITDA of $19.6M.
- Reiterates total Company net revenue guidance of $295 million to $315 million vs. consensus of $302.96M; adjusted non-GAAP EBITDA guidance of $54 million to $60 million; adjusted non-GAAP Earnings Per Share between $1.34 and $1.62 vs. consensus of $1.37.
For further details see:
ANI Pharmaceuticals reports Q3 earnings miss; reaffirms FY22 guidance